Supplementary table 1: National (United Kingdom) criteria for treatment in patients with wet AMD.

|  |
| --- |
| National Institute of Health and Care Excellence funding guidance for patients treated with aflibercept |
| * Best-corrected visual acuity is between 6/12 and 6/96
* No permanent structural damage to the central fovea
* Lesion size is less than or equal to 12 disc areas in greatest linear dimension
* Evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)
* Best-corrected visual acuity is between 6/12 and 6/96 (approximate ETDRS letter score of 73 to 25 letters inclusive)
 |

Supplementary table 2: Anatomical and visual acuity outcomes of those who lost follow up

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Demographic data of all eyes at baseline** |  |
|  |  |  | **Total analysis of all eyes – 3 years follow up** |  |
|  | All eyes included in the analysis (completed 1 year of followup) | Lost to follow up between year 1 and 2 | Lost to follow up between year 2 and 3 | Lost follow up between year 3 and 4 | Completed 4 years follow-up | P |
| No. of eyes | 148 | 17 | 23 | 14 | 94 | P > 0.05 |
| No. of patients | 139 | 16 | 21 | 14 | 89 |
| Female (%) | 58.9% | 41.1% | 62.8% | 71.4% | 58.9% |
| Mean baseline age (SD),years | 80.6±8.3 | 81.6±8.1 | 81.4±10.2 | 77±10.8 | 80.6±8.6 |
| Mean baseline VA (Snellen; SD) | 54.4 ± 16 | 49.2±18.4 | 56±17.9 | 54.7±21.8 | 54.1 ±15.5 |
| Baseline VA≥ 73 letters (20/40; %) | 10.8% | 0% | 17.4% | 7.4% | 9.6% |
| Baseline VA≤ 35 letters (20/200; %) | 19.6% | 29.4% | 21.7% | 21.4% | 20.2% |
| Central subfield macular thickness  | 300.3 ± 92.6 | 318.8±119 | 299.2±84.6 | 292.83±120 | 218.4±81 |

Supplementary figure 1. Median and interquartile range calculations